BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 31064563)

  • 1. Incorporating Household Spillovers in Cost Utility Analysis: A Case Study Using Behavior Change in COPD.
    Bhadhuri A; Al-Janabi H; Jowett S; Jolly K
    Int J Technol Assess Health Care; 2019 Jan; 35(3):212-220. PubMed ID: 31064563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Comparison of the Validity and Responsiveness of the EQ-5D-5L and SF-6D for Measuring Health Spillovers: A Study of the Family Impact of Meningitis.
    Bhadhuri A; Jowett S; Jolly K; Al-Janabi H
    Med Decis Making; 2017 Nov; 37(8):882-893. PubMed ID: 28525725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?
    Yang F; Devlin N; Luo N
    Value Health; 2019 Jan; 22(1):45-49. PubMed ID: 30661633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of the COPD Patient Management European Trial home-based disease management program.
    Bourbeau J; Granados D; Roze S; Durand-Zaleski I; Casan P; Köhler D; Tognella S; Viejo JL; Dal Negro RW; Kessler R
    Int J Chron Obstruct Pulmon Dis; 2019; 14():645-657. PubMed ID: 30936689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic Evaluation of Community-Based Case Management of Patients Suffering From Chronic Obstructive Pulmonary Disease.
    Sørensen SS; Pedersen KM; Weinreich UM; Ehlers L
    Appl Health Econ Health Policy; 2017 Jun; 15(3):413-424. PubMed ID: 27928660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.
    Spencer M; Briggs AH; Grossman RF; Rance L
    Pharmacoeconomics; 2005; 23(6):619-37. PubMed ID: 15960557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Utility Analysis of Telemonitoring Interventions for Patients with Chronic Obstructive Pulmonary Disease (COPD) in Germany.
    Hofer F; Achelrod D; Stargardt T
    Appl Health Econ Health Policy; 2016 Dec; 14(6):691-701. PubMed ID: 27475635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone in Patients with COPD-A Cost-Effectiveness Analysis in the Czech Republic.
    Skoupa J; Kasak V; Klimes J; Valena T
    Value Health Reg Issues; 2018 Sep; 16():112-118. PubMed ID: 30539739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.
    van Boven JF; Kocks JW; Postma MJ
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2191-2201. PubMed ID: 27703341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.
    Selya-Hammer C; Gonzalez-Rojas Guix N; Baldwin M; Ternouth A; Miravitlles M; Rutten-van Mölken M; Goosens LM; Buyukkaramikli N; Acciai V
    Ther Adv Respir Dis; 2016 Oct; 10(5):391-401. PubMed ID: 27405723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data.
    Briggs AH; Lozano-Ortega G; Spencer S; Bale G; Spencer MD; Burge PS
    Value Health; 2006; 9(4):227-35. PubMed ID: 16903992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of a brief education, self-management and upper limb exercise training in people with rheumatoid arthritis (EXTRA) programme: a trial-based analysis.
    Manning VL; Kaambwa B; Ratcliffe J; Scott DL; Choy E; Hurley MV; Bearne LM
    Rheumatology (Oxford); 2015 Feb; 54(2):302-9. PubMed ID: 25173349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring Health Spillovers for Economic Evaluation: A Case Study in Meningitis.
    Al-Janabi H; Van Exel J; Brouwer W; Trotter C; Glennie L; Hannigan L; Coast J
    Health Econ; 2016 Dec; 25(12):1529-1544. PubMed ID: 26464311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An economic evaluation of perioperative enteral nutrition in patients undergoing colorectal surgery (SANICS II study).
    Pattamatta M; Evers SMAA; Smeets BJJ; Peters EG; Luyer MDP; Hiligsmann M
    J Med Econ; 2019 Mar; 22(3):238-244. PubMed ID: 30523724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of sustained-release morphine for refractory breathlessness in COPD: A randomized clinical trial.
    Verberkt CA; van den Beuken-van Everdingen MHJ; Dirksen CD; Schols JMGA; Wouters EFM; Janssen DJA
    Respir Med; 2021 Apr; 179():106330. PubMed ID: 33611087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of differences in EQ-5D and SF-6D utility scores on the acceptability of cost-utility ratios: results across five trial-based cost-utility studies.
    Joore M; Brunenberg D; Nelemans P; Wouters E; Kuijpers P; Honig A; Willems D; de Leeuw P; Severens J; Boonen A
    Value Health; 2010; 13(2):222-9. PubMed ID: 19878492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease.
    Lock K; Wilson K; Murphy D; Riesco JA
    Expert Opin Pharmacother; 2011 Dec; 12(17):2613-26. PubMed ID: 22017336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 3-Year Cost-Effectiveness of a Nurse-Based Case Management versus Usual Care for Elderly Patients with Myocardial Infarction: Results from the KORINNA Follow-Up Study.
    Seidl H; Hunger M; Meisinger C; Kirchberger I; Kuch B; Leidl R; Holle R
    Value Health; 2017 Mar; 20(3):441-450. PubMed ID: 28292489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium.
    Hettle R; Wouters H; Ayres J; Gani R; Kelly S; Lion M; Decramer M
    Respir Med; 2012 Dec; 106(12):1722-33. PubMed ID: 23040833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.